Ultragenyx Pharmaceutical Inc.
RARE
$21.34
-$0.37-1.70%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 3.49% | -35.12% | 12.65% | 11.49% | -8.13% |
| Total Depreciation and Amortization | -7.88% | -1.72% | -2.74% | 1.64% | 16.04% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -10.06% | -5.24% | -32.44% | 18.86% | 21.13% |
| Change in Net Operating Assets | -97.42% | 77.95% | -233.35% | -1.10% | 71.63% |
| Cash from Operations | -25.86% | -36.46% | -40.68% | 12.72% | 5.47% |
| Capital Expenditure | -475.46% | 20.96% | -22.45% | 58.77% | 89.81% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -169.46% | 143.25% | 17.68% | 24.14% | 197.39% |
| Cash from Investing | -170.48% | 142.53% | 17.52% | 26.96% | 195.78% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -25.57% | -99.95% | -78.27% | -- | -99.11% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 13,285.13% | -99.98% | -78.27% | 370.69% | -99.11% |
| Foreign Exchange rate Adjustments | 66.32% | -76.94% | 549.69% | 313.25% | -276.61% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 815.69% | 107.89% | -86.55% | 53.64% | -82.82% |